⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 30, 2009Journal of Clinical Oncology

Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma

Matthew S. Davids Amanda Charlton Swee-Siang Ng Mei Ling Chong Kevin Laubscher Mohammed M. Dar Jeffrey P. Hodge Richie Soong Boon Cher Goh

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

10.1200/Jco.2009.21.8149

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davids et al. (2009) studied this question.

synapsesocial.com/papers/6aace8bb84308b7f2b3fe2b1 https://doi.org/10.1200/jco.2009.21.8149

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single InstitutionPrognostic Study · 2005 · 736 citations
2A Comprehensive Review of the Treatment of Merkel Cell CarcinomaPrognostic Study · 2007 · 126 citations
3Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinomaPrognostic Study · 1999 · 303 citations
4C-KIT Expression in Primary and Metastatic Merkel Cell CarcinomaOriginal Research · 2004 · 70 citations
5Platelet‐derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylateOriginal Research · 2007 · 31 citations

Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Research Triangle Park Foundation